News

The U.S. Food and Drug Administration (FDA) issued a draft guidance in 2013 to encourage research  in people at the earliest stages of Alzheimer’s disease, with no symptoms or no obvious symptoms. The update has had effect, with new clinical trials looking at Alzheimer’s patients without noticeable dementia, when they…

Researchers at the  the Salk Institute, in California, have shown, in a mouse study, that increasing the levels of a specific protein in the brain leads to improvement of memory deficits associated with Alzheimer’s disease. The new study, titled “Neuregulin 1 Improves Cognitive Deficits And Neuropathology In An Alzheimer’s…

Aducanumab, an amyloid-fighting medication being developed by Biogen for Alzheimer’s disease (AD), has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The treatment is currently being evaluated in two large-scale Phase 3 trials, both of which are recruiting Alzheimer’s patients. The FDA’s fast track program allows for faster…

The National Institutes of Health’s recent $40 million award over the next five years will provide a new stage of research for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), an NIH public-private partnership. The ADNI is supported by the Foundation for the National Institutes of Health (FNIH), which anticipates $20…

An air pollutant found in industrial areas, magnetite, could be contributing to the development of neurological conditions such as Alzheimer’s disease (AD), according to new study out of the United Kingdom and Mexico. The study, “Magnetite pollution nanoparticles in the human brain,” was recently published in the journal Proceedings of the…

An investigational treatment for Alzheimer’s disease (AD) could be on the horizon, according to a study from researchers at Biogen and the University of Zurich. Aducanumab, a human monoclonal antibody, shows evidence of reducing Alzheimer’s amyloid plaques — the culprit behind AD-induced brain cell death. The treatment candidate is potentially…

Researchers announced the start of what is being called the largest and most thorough study yet undertaken to identify biomarkers of Alzheimer’s disease before symptoms occur. Such findings could help determine the success of Alzheimer clinical trials and lead to earlier diagnoses. The British effort involves the translational research firm Imanova,…

At the recent Alzheimer’s Association International Conference (AAIC) 2016, held in Toronto, Canada, Muses Labs presented data from a pilot study of its MEND Protocol for treatment of early Alzheimer’s disease. The few drugs available today to slow the progression of Alzheimer’s disease target individual brain factors. Plenty of research,…

A variety of shark species from the Atlantic and Pacific Oceans have high concentrations of two toxins linked to neurodegenerative diseases like Alzheimer’s in their fins and muscles, according to researchers at the University of Miami. Their study, “Cyanobacterial Neurotoxin BMAA and Mercury in Sharks,”…

The rate of Alzheimer’s disease (AD) is increasing worldwide with the most significant risk factors appearing to be associated with diet, particularly the consumption of sweets, meat, and high-fat dairy products common in the Western diet, according to a new study report. For example, during Japan’s transition from the Japanese diet to the…